Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab Induction May Prevent Celiac Enteritis
Celiac disease (CD) is characterized as an autoimmune disorder whereby gluten (a protein
 found in wheat, barley, rye, malt) induces an immunological response in genetically
 susceptible individuals. The prevalence of CD has been estimated to affect 0.5-1% of the
 population worldwide. Long term sequelae are numerous and include risk of lymphoma,
 malabsorption leading to weight loss, anemia, multiple vitamin deficiencies,
 osteoporosis/osteopenia, secondary autoimmunity, etc. (1)
Adult subjects with CD will be recruited through our clinic. All patients enrolled will have
 established CD diagnosed > 6 months. All patients will have history of abnormal MARSH score
 on initial duodenal biopsy at diagnosis and MARSH 0 on repeat biopsy following a gluten free
 diet (GFD). All patients will also have positive celiac serologies (anti-TTG, anti-gliadin,
 etc.) at diagnosis, as well as, positive HLA DQ2/DQ8 genetic profile. At enrollment, all
 patients will have negative celiac serologies, indicative of serologic remission on a gluten
 free diet. Female subjects of childbearing potential (does not include those with history of
 tubal ligation/surgical sterilization, hysterectomy and/or oophorectomy) who are sexually
 active with a non-sterilized male partners agree to routinely use adequate contraception from
 signing informed consent, during study process and for an additional 18 weeks after the last
 dose of vedolizumab. A male subject who is non-sterilized and sexually active with a female
 partner of childbearing potential agrees to use adequate contraception from signing informed
 consent throughout the duration of the study and for 18 weeks after the last dose.
Inclusion Criteria:

 -  Patients must meet the following criteria for study entry:

 -  Adult patients with Celiac Disease (CD)

 -  Without any additional co-morbidities

 -  Normal renal and hepatic function

 -  Diagnosis of CD established at least 6 months prior to trial with diagnostic serology,
 genetic profile, endoscopic appearance and histopathology report In histologic and
 serologic remission (defined as MARSH 0 and negative anti-tissue transglutaminase,
 etc.) following a gluten free diet

 -  Naïve to treatment with vedolizumab

 -  Able and willing to provide written informed consent

 -  Eligibility criteria for laboratory profiles - healthy patient normal laboratory
 reference values

 -  WBC 4.5-12.0 k/UL

 -  Platelet count- 140-415 k/UL

 -  Hemoglobin- 11.0-17.4 %g/dL

 -  Renal Function-

 -  Creatinine- 0.5-1.3 mg/dL

 -  BUN- 5-20 mg/dL

 -  Hepatic Function

 -  Albumin - 3.3-5.0 g/dL

 -  INR- 0.9-1.1

 -  AST- 0-37 U/L

 -  ALT- 0-40 U/L

 -  Total Bilirubin- 0.1-1.3 mg/dL

 -  Alk Phos- 35-150 U/L

 Exclusion Criteria:

 -  Patients who meet any of the following criteria will be excluded from study entry:

 -  Abnormal MARSH score on enrollment histopathology

 -  Elevated celiac serologies (anti-tissue transglutaminase, etc.)

 -  Current use of biologics or immunomodulators Adalimumab, infliximab, Ustekinumab,
 Golimumab, Tocilizumab, Certolizumab, Etanercept, Rituximab, Anakinra, Abatacept,
 Tofacitinib, Methotrexate, Azathioprine, 6-MP.

 -  Current use of immunosuppressive therapy including intermittent systemic
 corticosteroids within two months of vedolizumab induction

 -  History of intestinal lymphoma (MALToma, etc.)

 -  History of cancer including hematologic malignancy, solid tumors, carcinoma in situ,
 etc.

 -  Pregnant or lactating

 -  Fertile females will require at least one form of birth control

 -  Lack of peripheral venous access

 -  Inability to comply with study protocol, in the opinion of the investigator

 -  Neurological conditions which may interfere with monitoring for PML

 -  History of demyelinating disease or history of major neurological disease

 -  History of alcohol, drug or chemical abuse < 6 months prior to screening

 -  History of active tuberculosis (TB) or a positive screening test for latent
 mycobacterium tuberculosis infection

 -  Positive PPD= > 10 mm or > 5mm in patients on 15 mg or more of prednisone

 -  History of BCG vaccination should be screened using Quantiferon TB Gold test

 -  An Indeterminate Quantiferon test will require a chest X-ray to rule out active TB and
 consultation with an infectious disease specialist to confirm the risk of latent

 -  TB is low and that patients can be safely enrolled in the trial

 -  History of recurrent opportunistic infections and/or of severe or disseminated viral
 infections

 -  Active autoimmune disease

 -  Active inflammatory bowel disease